Research ArticleBasic Science Investigations
Upregulation of Key Molecules for Targeted Imaging and Therapy
Vincent F. Taelman, Piotr Radojewski, Nicolas Marincek, Anat Ben-Shlomo, Andrea Grotzky, Cristina I. Olariu, Aurel Perren, Christoph Stettler, Thomas Krause, Lorenz P. Meier, Renzo Cescato and Martin A. Walter
Journal of Nuclear Medicine November 2016, 57 (11) 1805-1810; DOI: https://doi.org/10.2967/jnumed.115.165092
Vincent F. Taelman
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Piotr Radojewski
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Nicolas Marincek
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Anat Ben-Shlomo
3Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California
Andrea Grotzky
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Cristina I. Olariu
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Aurel Perren
4Institute of Pathology, University Bern, Bern, Switzerland
Christoph Stettler
5Division of Diabetes, Endocrinology, Nutritional Medicine & Metabolism, University Hospital and Inselspital, Bern, Switzerland; and
Thomas Krause
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Lorenz P. Meier
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Renzo Cescato
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
Martin A. Walter
1Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
2Clinical Radiopharmacy, Department of Clinical Research, University Hospital Bern, Bern, Switzerland
6Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 11
November 1, 2016
Upregulation of Key Molecules for Targeted Imaging and Therapy
Vincent F. Taelman, Piotr Radojewski, Nicolas Marincek, Anat Ben-Shlomo, Andrea Grotzky, Cristina I. Olariu, Aurel Perren, Christoph Stettler, Thomas Krause, Lorenz P. Meier, Renzo Cescato, Martin A. Walter
Journal of Nuclear Medicine Nov 2016, 57 (11) 1805-1810; DOI: 10.2967/jnumed.115.165092
Upregulation of Key Molecules for Targeted Imaging and Therapy
Vincent F. Taelman, Piotr Radojewski, Nicolas Marincek, Anat Ben-Shlomo, Andrea Grotzky, Cristina I. Olariu, Aurel Perren, Christoph Stettler, Thomas Krause, Lorenz P. Meier, Renzo Cescato, Martin A. Walter
Journal of Nuclear Medicine Nov 2016, 57 (11) 1805-1810; DOI: 10.2967/jnumed.115.165092
Jump to section
Related Articles
Cited By...
- Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors
- Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
- 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
- Combination Strategies to Improve Targeted Radionuclide Therapy
- Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
- Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
- Genetic and epigenetic drivers of neuroendocrine tumours (NET)